Skip to main content
Log in

Effects of propranololin vitro andin vivo on platelet function and thromboxane formation in normal volunteers

  • Histamine and Kinins
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

In vitro andex vivo effects of propranolol on platelet aggregation, formation of thromboxane B2 (TXB2) and platelet sensitivity to prostacyclin were studied in healthy men. Propranolol, addedin vitro to platelet rich plasma (PRP) inhibited platelet aggregation and TXB2 formation induced by ADP, 1-epinephrine, collagen and arachidonic acid. Concentration of 20–100 μM propranolol were effective when ADP, 1-epinephrine and collagen were used as stimuli. Higher concentrations (250–500 μM) were needed to inhibit aggregation induced by arachidonic acid. Oral administration of propranolol either as a single dose (120 mg) or for one week (3×40 mg/day) did, however, not affect platelet aggregation, thromboxane formation and platelet sensitivity to prostacyclin. In addition, withdrawal of propranolol was without effect on these parameters. Although propranolol has potent effects on platelet functionin vitro, it seems that the blood levels achievable by oral administration of propranolol are too low to affect platelet aggregation and TXB2 formation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. A.I. Schafer andR.I. Handin,The role of platelets in thrombotic and vascular disease, Prog. cardiovasc. Dis.22, 31–52 (1979).

    Article  PubMed  Google Scholar 

  2. J.I. Haft,Role of blood platelets in coronary artery disease, Am. J. Cardiol.43, 1197–1206 (1979).

    Article  PubMed  Google Scholar 

  3. L.A. Harker andJ.L. Ritchie,The role of platelets in acute vascular events, Circulation62, suppl. V, 13–18 (1980).

    Google Scholar 

  4. P.B. Oliva,Pathophysiology of acute myocardial infarction, Ann. intern. Med.94, 236–250 (1981).

    PubMed  Google Scholar 

  5. V. Fuster andJ.H. Chesebro,Antithrombotic therapy: role of platelet-inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets, Mayo Clin. Proc.56, 102–112 (1981).

    PubMed  Google Scholar 

  6. M. Hamberg, J. Svensson andB. Samuelsson,Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides, Proc. natn. Acad. Sci. USA72, 2994–2998 (1975).

    Google Scholar 

  7. M.L. Ogletree, J.B. Smith andA.M. Lefer,Actions of prostaglandins on isolated perfused cat coronary arteries, Am. J. Physiol.235, H400-H406 (1978).

    PubMed  Google Scholar 

  8. R.M. Norris, E.D. Clarke, N.L. Sammel, W.M. Smith andB. Williams,Protective effect of propranolol in threatened myocardial infarction, Lancetii, 907–909 (1978).

    Article  Google Scholar 

  9. P. Sleight,Beta-adrenergic blockade after myocardial infarction, New Engl. J. Med.304, 837–838 (1981).

    PubMed  Google Scholar 

  10. M.A. Packham andJ.F. Mustard,Pharmacology of platelet affecting drugs, Circulation62, suppl. V, 26–41 (1980).

    Google Scholar 

  11. S. Bygdeman andØ. Johnson,Studies on the effect of adrenergic blocking drugs on catecholamine-induced platelet aggregation and uptake of noradrenaline and 5-hydroxytryptamine, Acta physiol. scand.75, 129–138 (1969).

    PubMed  Google Scholar 

  12. H. Grobecker, B. Lemmer, D. Hellenbrecht andG. Wiethold,Inhibition of anti-arrythmic and beta-sympatholytic drugs of serotonin uptake by human platelets: Experiments in vitro and in vivo, Eur. J. Clin. Pharmac.5, 145–150 (1973).

    Article  Google Scholar 

  13. B.B. Weksler, M. Gillick andJ. Pink,Effect of propranolol on platelet function, Blood 49, 185–196 (1977).

    PubMed  Google Scholar 

  14. I. Nathan, A. Dvilansky, J. Sage andA.D. Korczyn,Effects of propranolol and pindolol on platelet aggregation and serotonin release, Life Sci.20, 407–412 (1977).

    Article  PubMed  Google Scholar 

  15. W.H. Frishmann, B. Weksler, J.P. Christodoulou, C. Smithen andT. Killip,Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol, Circulation50, 887–896 (1974).

    PubMed  Google Scholar 

  16. J. Mehta, P. Mehta andC.J. Pepine,Platelet aggregation in aortic and coronary venous blood in patients with and without coronary disease. Role of tachycardia stress and propranolol, Circulation58, 881–886 (1978).

    PubMed  Google Scholar 

  17. I. Keber, M. Jerse, D. Keber andM. Stegnar,The influence of combined treatment with propranolol and acetyl-salicylic acid on platelet aggregation in coronary heart disease, Br. J. Clin. Pharmac.7, 287–291 (1979).

    Google Scholar 

  18. M.A. Singer,Interaction of dibucaine and propranolol with phospholipid bilayer membranes. Effect of alterations in fatty acyl composition, Biochem. Pharmac.26, 51–57 (1977).

    Article  Google Scholar 

  19. J. Dachary-Prigent, J. Dufourcq, C. Lussan andM. Boisseau,Propranolol, chlorpromazine and platelet membrane: a fluorescence study of the drugmembrane interaction, Thromb. Res.14, 15–22 (1979).

    Article  PubMed  Google Scholar 

  20. M. Volpi, R.I. Sha'afi, P.M. Epstein, D.M. Andrenyak andM.B. Feinstein,Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin, Proc. natn. Acad. Sci. USA78, 795–799 (1981).

    Google Scholar 

  21. J.Y. Vanderhoek andM.B. Feinstein,Local anesthetics, chlorpromazine and propranolol inhibit stimulus-activation of phospholipase A 2 in human platelets, Mol. Pharmac.16, 171–180 (1979).

    Google Scholar 

  22. E.G. Lapetina,Regulation of arachidonic acid production: role of phospholipases C and A 2. Trends in Pharmac. Sci.3, 115–118 (1982).

    Article  Google Scholar 

  23. J.G. White andJ.M. Gerrard, Platelet morphology and the ultrastructure of regulatory mechanisms involved in platelet activation. InPlatelets: A Multidisciplinary Approach, pp. 17–34 (Eds.G. de Gaetano andS. Garratini). Raven Press, New York 1978.

    Google Scholar 

  24. R.R. Gorman,Modulation of human platelet function by prostacyclin and thromboxane A 2, Fedn Proc.38, 83–88 (1979).

    Google Scholar 

  25. W. Siess, P. Roth andP.C. Weber,Stimulated platelet aggregation, thromboxane B 2 formation and platelet sensitivity to prostacyclin — a critical evaluation, Thromb. Haemost.54, 204–207 (1981).

    Google Scholar 

  26. R. Lorenz, W. Siess andP.C. Weber,Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man, Eur. J. Pharmac.70, 511–518 (1981).

    Article  Google Scholar 

  27. G.V.R. Born,Aggregation of blood platelets by adenosine diphosphate and its reversal, Nature194, 927–929 (1962).

    PubMed  Google Scholar 

  28. J.D. Peuler andG.A. Johnson,Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine, Life Sci.21, 625–636 (1977).

    Article  PubMed  Google Scholar 

  29. E. Haber, T. Koerner, L.B. Page, B. Kliman andA. Purnode,Application of a radioimmunoassay for angiotensin I to the physiologic measurement of plasma renin activity in normal human subjects, J. clin. Endocr. Metab.29, 1349–1356 (1969).

    PubMed  Google Scholar 

  30. S.E. Epstein andE. Braunwald,Beta-adrenergic receptor blocking drugs: Mechanism of action and clinical applications, New Engl. J. Med.275, 1106–1112 (1966).

    PubMed  Google Scholar 

  31. M.E. Conolly, F. Kersting andC.T. Dollery,The clinical pharmacology of beta-adrenoceptor blocking drugs, Prog. cardiovas. Dis.19, 203–234 (1976).

    Article  Google Scholar 

  32. B.B. Vargaftig, M. Chignard andJ. Benveniste,Present concepts on the mechanisms of platelet aggregation, Biochem. Pharmac.30, 263–271 (1981).

    Article  Google Scholar 

  33. R.L. Kinlough-Rathbone, M.A. Packham, J. Reimers, J.P. Cazenave andJ.F. Mustard,Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23187, J. Lab. clin. Med.90, 707–719 (1977).

    PubMed  Google Scholar 

  34. H.W. Frishmann, J. Christodoulou, B. Weksler, C. Smithen, T. Killip andS. Scheidt,Abrupt propranolol withdrawal in angina pectoris: effects on platelet aggregation and exercise tolerance, Am. Heart J.95, 169–179 (1978).

    Article  PubMed  Google Scholar 

  35. N.D. Vlachakis andF.L. Aledort,Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation, Am. J. Cardiol.45, 321–325 (1980).

    Article  PubMed  Google Scholar 

  36. N. Salky andM. Dugdale,Platelet abnormalities in ischemic disease, Am. J. Cardiol.32, 612–617 (1973).

    PubMed  Google Scholar 

  37. J.F. Mustard andM.A. Packham,Platelets and diabetes mellitus, New Engl. J. Med.297, 1345–1347 (1977).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This study was supported by a grant (We 681) from DFG, Bonn, FRG.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siess, W., Lorenz, R., Roth, P. et al. Effects of propranololin vitro andin vivo on platelet function and thromboxane formation in normal volunteers. Agents and Actions 13, 29–34 (1983). https://doi.org/10.1007/BF01994278

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01994278

Keywords

Navigation